title: Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population.
abstract: Despite advances in graft-versus-host-disease (GVHD) treatment, it is estimated that overall survival (OS) at 2 years for hematopoietic cell transplantation (HCT) recipients who experience steroid-resistant GVHD is 10%. Among recent therapeutic approaches for GVHD treatment, mesenchymal stromal cells (MSCs) hold a key position. We describe a multicenter experience of 11 pediatric patients diagnosed with acute or chronic GVHD (aGVHD, cGVHD) treated for compassionate use with GMP-grade unrelated HLA-disparate donors' bone marrow-derived MSCs, expanded in platelet-lysate (PL)-containing medium. Eleven patients (aged 4-15 years) received intravenous (i.v.) MSCs for aGVHD or cGVHD, which was resistant to multiple lines of immunosuppression. The median dose was 1.2 x 10(6)/kg (range: 0.7-3.7 x 10(6)/kg). No acute side effects were observed, and no late side effects were reported at a median follow-up of 8 months (range: 4-18 months). Overall response was obtained in 71.4% of patients, with complete response in 23.8% of cases. None of our patients presented GVHD progression upon MSC administration, but 4 patients presented GVHD recurrence 2 to 5 months after infusion. Two patients developed chronic limited GVHD. This study underlines the safety of PL-expanded MSC use in children. MSC efficacy seems to be greater in aGVHD than in cGVHD, even after failure of multiple lines of immunosuppression.
authors.affiliation: Clinica Pediatrica, Università Milano Bicocca, Ospedale San Gerardo, Via Donizetti 106, Monza, MI, Italy.
authors.forename: Giovanna
authors.initials: G
authors.lastname: Lucchini
authors.forename: Martino
authors.initials: M
authors.lastname: Introna
authors.forename: Erica
authors.initials: E
authors.lastname: Dander
authors.forename: Attilio
authors.initials: A
authors.lastname: Rovelli
authors.forename: Adriana
authors.initials: A
authors.lastname: Balduzzi
authors.forename: Sonia
authors.initials: S
authors.lastname: Bonanomi
authors.forename: Agnese
authors.initials: A
authors.lastname: Salvadè
authors.forename: Chiara
authors.initials: C
authors.lastname: Capelli
authors.forename: Daniela
authors.initials: D
authors.lastname: Belotti
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Gaipa
authors.forename: Paolo
authors.initials: P
authors.lastname: Perseghin
authors.forename: Paola
authors.initials: P
authors.lastname: Vinci
authors.forename: Edoardo
authors.initials: E
authors.lastname: Lanino
authors.forename: Patrizia
authors.initials: P
authors.lastname: Chiusolo
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Orofino
authors.forename: Sarah
authors.initials: S
authors.lastname: Marktel
authors.forename: Jose
authors.initials: J
authors.lastname: Golay
authors.forename: Alessandro
authors.initials: A
authors.lastname: Rambaldi
authors.forename: Andrea
authors.initials: A
authors.lastname: Biondi
authors.forename: Giovanna
authors.initials: G
authors.lastname: D'Amico
authors.forename: Ettore
authors.initials: E
authors.lastname: Biagi
mesh_terms: D000293:Adolescent; D001792:Blood Platelets / Q000166:cytology / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D057176:Compassionate Use Trials; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology / Q000628:therapy*; D006801:Humans; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000276:immunology*; D016879:Salvage Therapy / Q000379:methods*; D017154:Stromal Cells / Q000166:cytology / Q000276:immunology*